Overview

BioPharma Credit : BPCR

BioPharma Credit plc provides investors with an opportunity to gain exposure to the fast growing life sciences industry, through a diversified portfolio of loans and other instruments backed by royalties or other cash flows derived from sales of approved life sciences products. BioPharma Credit’s primary objective is to generate predictable income for shareholders over the long term.
Once substantially invested, BioPharma Credit will target an annual dividend yield of 7 per cent. (calculated by reference to the Issue Price), and a net total return on NAV of 8 to 9 per cent. per annum in the medium term.

Pharmakon Advisors, the fund’s Investment Manager, was founded in 2009 and has invested US$1.3 billion in 20 transactions across four funds. The first three funds are now fully invested. Drawing upon the expertise and successful track record of Pharmakon Advisors, the fund enjoys access to its extensive, industry-focused knowledge and contacts to source, analyse and structure attractive investment opportunities.

Their website can be reached by clicking this link.

BPCR : BioPharma Credit

You can view our interviews with the company’s Fund Managers below:

24th June 2022: Pedro Gonzalez de Cosio – Weekly Show

Fundamentals

Ticker
BPCR
Exchange
XLON
Domicile
GBR
Sector
Financial Services
Market Capitalisation (M)
1016
Share Price (USD)
0.9
12 Month Trailing Dividend Yield
7.1%

Price

In The Press

Data